Union Budget 2026-27 Boosts Mission-Linked Science Projects While Core Research Funding Gaps Persist
The Union Budget 2026-27 emphasizes 'mission-mode' initiatives in biopharma, semiconductors, and carbon capture, but researchers express concern over stagnant core funding. While the 'Biopharma SHAKTI' program received ₹10,000 crore over five years, the Department of Science and Technology (DST) and Department of Biotechnology (DBT) have seen revised estimates lower than original budget allocations in previous years. Experts argue that while big-ticket missions look impressive, basic research, state universities, and core institutes face funding gaps and administrative delays. India's R&D expenditure remains low at 0.64-0.7% of GDP, significantly behind global peers.
Key Points
- The 'Biopharma SHAKTI' program is a major new initiative focused on non-communicable diseases and biosimilars.
- Core funding for DST and DBT has faced cuts in revised estimates, impacting long-term basic research.
- The budget prioritizes applied sectors like space and semiconductors over foundational scientific inquiry.
- India's R&D spending as a percentage of GDP has remained stagnant for years, hindering global competitiveness.
Exam Facts
- R&D Expenditure: 0.64-0.7% of GDP.
- New Program: Biopharma SHAKTI (₹10,000 crore over 5 years).
- Anusandhan National Research Foundation (ANRF) is the new body for research funding.
Read it. Retain it. Recall it.
Get spaced-repetition flashcards, daily quizzes and offline access — free on Android.